Atrys Health, S.A. (BME:ATRY)
Spain · Delayed Price · Currency is EUR 2.655
-0.005 (-0.19%)
Aug 7, 2026, 12:16 PM CET
Atrys Health Financials Overview
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 146.37 | 146.37 | 141.63 | 207 | 164.14 | 127.84 |
Revenue Growth | -23.16% | 3.35% | -31.58% | 26.11% | 28.39% | 268.23% |
Gross Profit Gross Profit Growth | -11.15 | 30.86 | 40.73 | 62.12 | 51.11 | 34.41 |
Operating Income Operating Income Growth | -41.74 | -41.74 | -12.65 | -1.84 | -13.37 | -15.01 |
Net Income Net Income Growth | -100.3 | -100.3 | -31.77 | -45.59 | -23.15 | -23.26 |
Earnings Per Share EPS Growth | -1.32 | -1.32 | -0.42 | -0.60 | -0.34 | -0.46 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Medicine Precision - Diagnosis Medicine Precision - Diagnosis Growth | 68.84 | 68.84 | 71.39 | - | - |
Medicine Precision - Oncology Medicine Precision - Oncology Growth | 75.48 | 75.48 | 63.49 | 58.03 | 35.42 |
Total Total Growth | 144.31 | 144.31 | 134.88 | 206.1 | 163.2 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 13.07 | 13.07 | 20.37 | 41.83 | 34.3 | 35.13 |
Total Debt Total Debt Growth | 235.53 | 235.53 | 261.92 | 227.9 | 309.86 | 233.28 |
Net Cash (Debt) Net Cash Growth | -222.47 | -222.47 | -241.55 | -186.07 | -275.57 | -198.16 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -2.64 | -2.64 | -2.95 | -2.41 | -3.91 | -3.70 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -1.56 | -1.56 | 3 | 5.7 | -15.43 | 4.69 |
Capital Expenditures CapEx Growth | -12.52 | -12.52 | -4.25 | -13.15 | -15.16 | -8.57 |
Free Cash Flow Free Cash Flow Growth | -14.08 | -14.08 | -1.25 | -7.45 | -30.6 | -3.87 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | -7.62% | 21.08% | 28.75% | 30.01% | 31.14% | 26.92% |
Operating Margin | -28.52% | -28.52% | -8.93% | -0.89% | -8.14% | -11.74% |
Pretax Margin | -38.40% | -38.40% | -24.45% | -16.28% | -16.32% | -19.46% |
Profit Margin | -38.00% | -38.00% | -23.14% | -14.86% | -15.81% | -18.15% |
FCF Margin | -9.62% | -9.62% | -0.88% | -3.60% | -18.64% | -3.03% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | 46.00 | 17.00 | 156.74 | 25.81 | 29.58 | 36.01 |
PS Ratio | 1.40 | 1.52 | 1.81 | 1.35 | 2.87 | 4.87 |